Literature DB >> 3492218

Characterisation of a new murine B cell lymphoma.

L M Cobb, M J Glennie, H M McBride, G Breckon, T C Richardson.   

Abstract

The characterisation of a new murine B cell lymphoma, A31, is described. Histopathological examination of passaged tumour indicates that initial infiltration occurs in the spleen, lymph nodes, Peyer's patches and liver, while in the terminal phase the bone marrow, gonads and occasionally the central nervous system become involved. The terminal spread is coincidental with the leukaemic phase in the tumour. The tumour cells show typical B cell characteristics in vitro. These include surface immunoglobulin (Ig) of mu, kappa isotype, surface Ia, Thy-1 negativity and an increased uptake of tritiated thymidine following incubation with lipopolysaccharide. A31 cells secrete low levels of IgM into the tissue culture fluid. Short-term culture produced only 100 ng IgM per 10(7) cells over 8 h and no tumour-associated monoclonal band could be detected in the serum of tumour-bearing mice. Chromosomal karyotypes of A31 cells gave model numbers 2n=40 normal, and 2n=41, with partial trisomy of chromosome 2, and trisomy of 17. There was loss of a chromosome 6 and the Y chromosome, together with the translocation of part of an 11 to one of the two unidentified marker chromosomes. The responses of lymphoma-bearing mice to therapeutic levels of cyclophosphamide and vincristine sulphate and also to whole body X-radiation are illustrated. This tumour may help in unravelling the complex biology of B cell lymphoma and because of its low level of Ig secretion, be of particular value in experimental immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492218      PMCID: PMC2001547          DOI: 10.1038/bjc.1986.244

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

2.  Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen.

Authors:  J Gordon; G T Stevenson
Journal:  Immunology       Date:  1981-01       Impact factor: 7.397

3.  Isolation and characterization of leukaemic B-lymphocytes: influence of anticoagulant on C3-receptor detection, humoral killing and capping of cell surface immunoglobulin.

Authors:  J Gordon; V A Anderson
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

4.  Chromosomal aberrations observed in 52 mouse myeloid leukemias.

Authors:  I Hayata; M Seki; K Yoshida; K Hirashima; T Sado; J Yamagiwa; T Ishihara
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

5.  Glucocorticoid effects on lipopolysaccharide-stimulated murine B-cell leukemia line (BCL1) cells.

Authors:  D A Roess; T S Ruh; C J Bellone; M F Ruh
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

Review 6.  Acute lymphoid leukemia.

Authors:  W A Bleyer
Journal:  Pediatr Ann       Date:  1983-04       Impact factor: 1.132

7.  Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.

Authors:  D G Gilliland; Z Steplewski; R J Collier; K F Mitchell; T H Chang; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

8.  Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.

Authors:  M J Embleton; G F Rowland; R G Simmonds; E Jacobs; C H Marsden; R W Baldwin
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

9.  Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces.

Authors:  T J Hamblin; A K Abdul-Ahad; J Gordon; F K Stevenson; G T Stevenson
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

10.  Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes.

Authors:  F K Stevenson; T J Hamblin; G T Stevenson; A L Tutt
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

View more
  2 in total

1.  The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Authors:  Anna H Turaj; Khiyam Hussain; Kerry L Cox; Matthew J J Rose-Zerilli; James Testa; Lekh N Dahal; H T Claude Chan; Sonya James; Vikki L Field; Matthew J Carter; Hyung J Kim; Jonathan J West; Lawrence J Thomas; Li-Zhen He; Tibor Keler; Peter W M Johnson; Aymen Al-Shamkhani; Stephen M Thirdborough; Stephen A Beers; Mark S Cragg; Martin J Glennie; Sean H Lim
Journal:  Cancer Cell       Date:  2017-11-30       Impact factor: 31.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.